• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MicroRNA 沉默与肝脏疾病新型治疗方法的开发。

MicroRNA silencing and the development of novel therapies for liver disease.

机构信息

Department of Medicine, University of Massachusetts Medical School, MA 01605, United States.

出版信息

J Hepatol. 2012 Aug;57(2):462-6. doi: 10.1016/j.jhep.2012.01.030. Epub 2012 Apr 12.

DOI:10.1016/j.jhep.2012.01.030
PMID:22504335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4186651/
Abstract

In recent years microRNAs have emerged as crucial small non-coding RNA molecules with diverse roles in various diseases including diseases of the liver. In this review, we highlight the latest advances in the field of microRNA biology and their potential as emerging therapeutic targets in liver disease.

摘要

近年来， microRNAs 作为重要的小非编码 RNA 分子，在各种疾病中发挥着多样化的作用，包括肝脏疾病。在这篇综述中，我们重点介绍了 microRNA 生物学领域的最新进展及其作为肝脏疾病新兴治疗靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7777/4186651/d8548d44d4a1/nihms-632305-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7777/4186651/d8548d44d4a1/nihms-632305-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7777/4186651/d8548d44d4a1/nihms-632305-f0001.jpg

相似文献

1
MicroRNA silencing and the development of novel therapies for liver disease.MicroRNA 沉默与肝脏疾病新型治疗方法的开发。
J Hepatol. 2012 Aug;57(2):462-6. doi: 10.1016/j.jhep.2012.01.030. Epub 2012 Apr 12.
2
MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules.miR-122 作为寡核苷酸和小分子的治疗靶点。
Curr Med Chem. 2013;20(29):3629-40. doi: 10.2174/0929867311320290009.
3
MicroRNA-induced silencing in epilepsy: Opportunities and challenges for clinical application.微小RNA诱导的癫痫沉默：临床应用的机遇与挑战
Dev Dyn. 2018 Jan;247(1):94-110. doi: 10.1002/dvdy.24582. Epub 2017 Oct 4.
4
A perspective on RNA interference-based therapeutics for metabolic liver diseases.代谢性肝脏疾病的 RNA 干扰治疗的观点。
Expert Opin Investig Drugs. 2021 Mar;30(3):237-244. doi: 10.1080/13543784.2021.1879792. Epub 2021 Jan 29.
5
MicroRNA silencing in primates: towards development of novel therapeutics.灵长类动物中的微小RNA沉默：新型疗法的开发进展
Cancer Res. 2009 Jan 15;69(2):393-5. doi: 10.1158/0008-5472.CAN-08-2749.
6
MicroRNAs as novel biological targets for detection and regulation.微小 RNA 作为新型生物靶标用于检测和调控。
Chem Soc Rev. 2014 Jan 21;43(2):506-17. doi: 10.1039/c3cs60312a.
7
An overview of microRNAs.微小RNA概述
Adv Drug Deliv Rev. 2015 Jun 29;87:3-14. doi: 10.1016/j.addr.2015.05.001. Epub 2015 May 12.
8
Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids.利用锁核酸靶向 microRNA-122 来抗击丙型肝炎病毒。
Curr Gene Ther. 2012 Aug;12(4):301-6. doi: 10.2174/156652312802083558.
9
Toward microRNA-based therapeutics for heart disease: the sense in antisense.迈向基于微小RNA的心脏病治疗：反义中的意义。
Circ Res. 2008 Oct 24;103(9):919-28. doi: 10.1161/CIRCRESAHA.108.183426.
10
Liver as a target for oligonucleotide therapeutics.肝脏作为寡核苷酸治疗药物的靶标。
J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.

引用本文的文献

1
Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs.探讨非编码 RNA 在非酒精性脂肪性肝病中的调控作用：特别关注过氧化物酶体增殖物激活受体。
Cells. 2022 Dec 7;11(24):3959. doi: 10.3390/cells11243959.
2
Potential relative quantities of miR-122 and miR-150 to differentiate hepatocellular carcinoma from liver cirrhosis.miR-122和miR-150用于区分肝细胞癌与肝硬化的潜在相对量。
Noncoding RNA Res. 2022 Feb 6;7(1):34-39. doi: 10.1016/j.ncrna.2022.01.004. eCollection 2022 Mar.
3
Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.潜在的血浆生物标志物：miRNA-29c、miRNA-21 和 miRNA-155 在肝癌患者的临床进展中的作用。
PLoS One. 2022 Feb 14;17(2):e0263298. doi: 10.1371/journal.pone.0263298. eCollection 2022.
4
Hepatic stellate cell-derived exosomes modulate macrophage inflammatory response.肝星状细胞衍生的外泌体调节巨噬细胞炎症反应。
Exp Cell Res. 2021 Aug 1;405(1):112663. doi: 10.1016/j.yexcr.2021.112663. Epub 2021 May 26.
5
Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway.miR-188-5p 的抑制通过 PTEN/PI3K/AKT 通路显著减少 HSCs 的活化和增殖，从而减轻肝纤维化。
J Cell Mol Med. 2021 Apr;25(8):4073-4087. doi: 10.1111/jcmm.16376. Epub 2021 Mar 10.
6
Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy.拮抗 circRNA_002581-miR-122-CPEB1 轴通过恢复 PTEN-AMPK-mTOR 通路调节的自噬来减轻 NASH。
Cell Death Dis. 2020 Feb 13;11(2):123. doi: 10.1038/s41419-020-2293-7.
7
Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease.非编码RNA在非酒精性脂肪性肝病发生发展中的作用
Biomed Res Int. 2019 Feb 26;2019:8690592. doi: 10.1155/2019/8690592. eCollection 2019.
8
Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice.靶向小鼠肝 miR-221/222 治疗非酒精性脂肪性肝炎。
EBioMedicine. 2018 Nov;37:307-321. doi: 10.1016/j.ebiom.2018.09.051. Epub 2018 Oct 10.
9
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.酒精性脂肪性肝炎和非酒精性脂肪性肝炎的治疗机会：从发病机制的异同中寻找突破。
JCI Insight. 2017 Sep 7;2(17). doi: 10.1172/jci.insight.95354.
10
MiRNA-211 suppresses cell proliferation, migration and invasion by targeting SPARC in human hepatocellular carcinoma.微小RNA-211通过靶向分泌性酸性富含半胱氨酸蛋白抑制人肝癌细胞的增殖、迁移和侵袭。
Sci Rep. 2016 May 27;6:26679. doi: 10.1038/srep26679.

本文引用的文献

1
Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.小干扰 RNA（siRNA）、短发夹 RNA（shRNA）和微小 RNA（miRNA）的亚细胞命运和脱靶效应。
Pharm Res. 2011 Dec;28(12):2996-3015. doi: 10.1007/s11095-011-0608-1. Epub 2011 Oct 28.
2
miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components.miR-122 通过一种特殊的机制激活丙型肝炎病毒的翻译，该机制需要特定的 RNA 成分。
Nucleic Acids Res. 2011 Sep 1;39(17):7716-29. doi: 10.1093/nar/gkr426. Epub 2011 Jun 7.
3
MicroRNA delivery by cationic lipoplexes for lung cancer therapy.阳离子脂质体介导的 microRNA 递送至肺癌治疗。
Mol Pharm. 2011 Aug 1;8(4):1381-9. doi: 10.1021/mp2002076. Epub 2011 Jun 20.
4
microRNAs: fad or future of liver disease.微小 RNA：肝脏疾病的风尚还是未来。
World J Gastroenterol. 2011 May 28;17(20):2536-42. doi: 10.3748/wjg.v17.i20.2536.
5
RNAi-based therapeutic strategies for metabolic disease.基于 RNAi 的代谢疾病治疗策略。
Nat Rev Endocrinol. 2011 Apr 19;7(8):473-84. doi: 10.1038/nrendo.2011.57.
6
MicroRNAs and liver disease.微小 RNA 与肝脏疾病。
Transl Res. 2011 Apr;157(4):241-52. doi: 10.1016/j.trsl.2011.01.008. Epub 2011 Feb 2.
7
The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families.肝纤维化的进展与 miR-199 和 200 家族的过表达有关。
PLoS One. 2011 Jan 24;6(1):e16081. doi: 10.1371/journal.pone.0016081.
8
Silencing microRNA by interfering nanoparticles in mice.干扰纳米颗粒在小鼠中沉默 microRNA。
Nucleic Acids Res. 2011 Mar;39(6):e38. doi: 10.1093/nar/gkq1307. Epub 2011 Jan 6.
9
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver.载有肝特异性 microRNA-122 靶序列的 AAV 载体可有效抑制肝脏中转基因的表达。
Gene Ther. 2011 Apr;18(4):403-10. doi: 10.1038/gt.2010.157. Epub 2010 Dec 9.
10
Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles.利用 cRGD 功能化纳米粒靶向递送 miRNA 反义抑制剂进行抗血管生成治疗。
Mol Pharm. 2011 Feb 7;8(1):250-9. doi: 10.1021/mp100315q. Epub 2010 Dec 21.